Browse All

Current Filters

CLEAR FILTER x

TITLE

Longer-term (Up to 6 Years) Efficacy of Ofatumumab in People with Recently Diagnosed and Treatment-naive Relapsing Multiple Sclerosis

Author:Pardo, Gabriel   Hauser, Stephen   Bar-Or, Amit   Gold, Ralf   Montalban, Xavier   Cohen, Jeffrey   Robertson, Derrick   Hersh, Carrie   Naismith, Robert   Deiva, Kumaran   Bhatt, Alit   Fu, Haoyi   Boer, Ibolya   Meuth, Sven   Cross, Anne   Gärtner, Jutta   Kappos, Ludwig   

Session Name:S31: Multiple Sclerosis: Therapeutics and Clinical Decision Making  

Topic:Multiple Sclerosis  

Program Number:S31.003  

Author Institution:Oklahoma Medical Research Foundation, Oklahoma, USA, Oklahoma City, OK  UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA, San Francisco, CA  Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA  Department of Neurology, Katholisches Klinikum Bochum, Ruhr-Universität Bochum, Bochum, Germany, Bochum, Germany  Department of Neurology Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona, Spain, Barcelona, Spain  Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH  Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, Florida, USA, Tampa, FL  Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, United States, Las Vegas, NV  Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA, Saint Louis, MO  Department of Pediatric Neurology, University Hospitals Paris Saclay, Hôpital Bicêtre, National Reference Center for Rare Inflammatory Brain and Spinal Diseases, Le Kremlin Bicêtre, France, Le Kremlin Bicêtre, France  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Department of Neurology, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, Duesseldorf, Germany  Department of Neurology, Section of Neuroimmunology, Washington University School of Medicine, Saint Louis, Missouri, USA, Clayton, MO  Department of Paediatrics and Adolescent Medicine, Division of Paediatric Neurology, University Medical Centre Göttingen, Georg August University Göttingen, Göttingen, Germany, Göttingen, Germany  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Organs, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  

Prognostic Value of On-treatment Serum Neurofilament Light Chain for New or Enlarging T2 Lesions in People with Relapsing Multiple Sclerosis: Pooled Analysis of the ASCLEPIOS I/II Trials

Author:Leist, Thomas   Hauser, Stephen   Derfuss, Tobias   Wiendl, Heinz   Arnold, Douglas   Montalban, Xavier   Bhatt, Alit   Wei, Wenjia   Boer, Ibolya   Alvarez, Enrique   Ziemssen, Tjalf   

Session Name:S42: Multiple Sclerosis: Biomarkers/Neuroimaging  

Topic:Multiple Sclerosis  

Program Number:S42.003  

Author Institution:Thomas Jefferson University, Philadelphia, PA, USA, Philadelphia, PA  UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA, San Francisco, CA  Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland, Basel, Switzerland  Institute of Translational Neurology, University of Münster, Münster, Germany, Muenster, Germany  Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada, Montreal, QC, Canada  Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d’Hebron University Hospital, Barcelona, Spain, Barcelona, Spain  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Basel, Switzerland  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Novartis Pharma AG, Basel, Switzerland , Basel, Switzerland  Rocky Mountain MS Center, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO  Center of Clinical Neuroscience, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany  

Patient and Physician Perspectives on the Wearing-off Effect in Multiple Sclerosis: Results from Structured Interviews

Author:Alvarez, Enrique   Fielding, Joanne   Clement, Ivan John   Khazhaei, Dorsa   Jimenez-Moreno, Cecilia   Bushnell, Donald   Pata, Diogo   Paratt, John   

Session Name:P1: Multiple Sclerosis: Clinical Practice and Decision Making 1  

Topic:Multiple Sclerosis  

Program Number:P1.015  

Author Institution:Department of Neurology, Rocky Mountain MS Center at the University of Colorado, Aurora, Colorado, USA, Aurora, CO  Department of Neuroscience, Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia, Victoria, Australia  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Evidera-PPD, Bethesda, MD 20814 USA, Bethesda, MD  Department of Neurology, Royal North Shore Hospital, Sydney, Australia, Sydney, Australia  

Prognostic Value of Serum Neurofilament Light Chain for Disease Activity in Patients with Relapsing Multiple Sclerosis: Results from Subgroup Analysis Based on Body Mass Index and Age from the Phase 3 ASCLEPIOS I/II Trials

Author:Cross, Anne   Ziemssen, Tjalf   Arnold, Douglas   Thouvenot, Eric   Zamvil, Scott   Bhatt, Alit   Wei, Wenjia   Boer, Ibolya   Alvarez, Enrique   Wiendl, Heinz   

Session Name:P6: Multiple Sclerosis: Clinical Assessments Including Digital Tools and Outcome Measures 2  

Topic:Multiple Sclerosis  

Program Number:P6.011  

Author Institution:Washington University School of Medicine, Saint Louis, MO, USA, Saint Louis, MO  Center of Clinical Neuroscience, Department of Neurology, University Clinic Carl-Gustav Carus, Dresden, Germany, Dresden, Germany  Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada  Department of Neurology, Centre Hospitalier Universitaire (CHU) Nîmes, University of Montpellier, Nîmes, France  Institut de Génomique Fonctionnelle, UMR, Institut National de la Santé et de la Recherche Médicale (INSERM), University of Montpellier, Montpellier, France, Nimes Cedex 9, France  UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA, San Francisco, CA  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Department of Neurology, Rocky Mountain MS Center at the University of Colorado, Aurora, CO, USA, Aurora, CO  University of Münster, Münster, Germany, Muenster, Germany  

B-Cell Depletion and Efficacy Outcomes of Ofatumumab Are Consistent Across Different Body Mass Index Categories: Insights from ASCLEPIOS I and II Trials

Author:Cross, Anne   Hauser, Stephen   Wiendl, Heinz   Bar-Or, Amit   Coyle, Patricia   Montalban, Xavier   De Seze, Jerome   Fu, Haoyi   Bhatt, Alit   Boer, Ibolya   Kappos, Ludwig   

Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

Topic:Multiple Sclerosis  

Program Number:P9.002  

Author Institution:Washington University School of Medicine, Saint Louis, MO, USA, Clayton, MO  UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA, San Francisco, CA  University of Münster, Münster, Germany, Muenster, Germany  Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, PA, USA, Philadelphia, PA  Department of Neurology, Stony Brook University, Stony Brook, NY, USA, Stony Brook, NY  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Barcelona, Spain, Barcelona, Spain  University Hospital of Strasbourg, Strasbourg, France, Strasbourg, France  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Headorgans, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland